Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Dexcom Inc (NASDAQ: DXCM) closed at $79.96 in the last session, down -0.26% from day before closing price of $80.17. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 4.22 million shares were traded. DXCM stock price reached its highest trading level at $81.51 during the session, while it also had its lowest trading level at $79.87.
Ratios:
We take a closer look at DXCM’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 54.93. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.52. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 0.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $102.
On May 30, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $104.
On April 10, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $85.Mizuho initiated its Outperform rating on April 10, 2025, with a $85 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 28 ’25 when Stern Sadie sold 1,466 shares for $88.99 per share. The transaction valued at 130,459 led to the insider holds 106,689 shares of the business.
SADIE STERN bought 1,466 shares of DXCM for $130,459 on Jul 28 ’25. On Jul 15 ’25, another insider, FOLETTA MARK G, who serves as the Director of the company, sold 2,750 shares for $85.17 each. As a result, the insider received 234,217 and left with 53,871 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 31356715008 and an Enterprise Value of 31006734336. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 55.98, and their Forward P/E ratio for the next fiscal year is 30.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.29 while its Price-to-Book (P/B) ratio in mrq is 12.19. Its current Enterprise Value per Revenue stands at 7.21 whereas that against EBITDA is 33.583.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.49, which has changed by 0.10503042 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $93.25, while it has fallen to a 52-week low of $57.52. The 50-Day Moving Average of the stock is -4.20%, while the 200-Day Moving Average is calculated to be 0.65%.
Shares Statistics:
According to the various share statistics, DXCM traded on average about 3.46M shares per day over the past 3-months and 5058630 shares per day over the past 10 days. A total of 392.20M shares are outstanding, with a floating share count of 387.01M. Insiders hold about 1.31% of the company’s shares, while institutions hold 96.20% stake in the company. Shares short for DXCM as of 1753920000 were 8486867 with a Short Ratio of 2.45, compared to 1751241600 on 10514753. Therefore, it implies a Short% of Shares Outstanding of 8486867 and a Short% of Float of 2.77.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Dexcom Inc (DXCM) involves the perspectives of 23.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.68, with high estimates of $0.74 and low estimates of $0.63.
Analysts are recommending an EPS of between $2.15 and $1.91 for the fiscal current year, implying an average EPS of $2.05. EPS for the following year is $2.56, with 24.0 analysts recommending between $2.91 and $2.3.
Revenue Estimates
According to 22 analysts, the current quarter’s revenue is expected to be $1.18B. It ranges from a high estimate of $1.21B to a low estimate of $1.15B. As of the current estimate, Dexcom Inc’s year-ago sales were $994.2MFor the next quarter, 22 analysts are estimating revenue of $1.25B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.23B.
A total of 25 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.68B, while the lowest revenue estimate was $4.61B, resulting in an average revenue estimate of $4.62B. In the same quarter a year ago, actual revenue was $4.03BBased on 25 analysts’ estimates, the company’s revenue will be $5.34B in the next fiscal year. The high estimate is $5.65B and the low estimate is $5.1B.
